仙乐健康拟冲刺A+H上市，预计2025年净利同比“腰斩”

Core Viewpoint - Xianle Health, a leading health supplement OEM, has submitted an application for a dual listing on the Hong Kong Stock Exchange, while simultaneously announcing a significant decline in net profit for the previous year [1][2] Group 1: Company Performance - Xianle Health's revenue for 2023, 2024, and the first three quarters of 2025 is projected to be 3.582 billion, 4.211 billion, and 3.291 billion yuan respectively, with net profit growth rates declining significantly to 32.39%, 15.66%, and 8.53% [1] - The company expects a net profit attributable to shareholders for 2025 to be between 101 million and 151 million yuan, representing a year-on-year decline of 53% to 69% [2] - The net profit margin for the same periods is reported at 6.71%, 6.7%, and 6.74%, indicating a stable but low profitability [1] Group 2: Business Strategy and Adjustments - The decline in net profit is attributed to a one-time asset impairment loss of 195 million yuan from the personal care business, which has been underperforming and is being divested [2] - The company is focusing on strategic consulting projects and investments in emerging sectors such as precision nutrition and pet nutrition, which have incurred initial costs affecting profit margins [2] - A new stock incentive plan has been proposed, aiming to grant 2.2025 million restricted shares to 85 key personnel, with revenue targets set for 2026 to 2028 but no profit-related metrics, raising concerns among investors [3] Group 3: Market Outlook and Analyst Opinions - Analysts express optimism regarding Xianle Health's growth in European and Asia-Pacific markets, suggesting that the company can leverage international capital markets to enhance its global strategy [4] - The divestment of the personal care business allows the company to concentrate on its core operations, potentially leading to improved profitability and growth in both domestic and international markets [4] - Analysts recommend monitoring the company's performance as it aims for accelerated growth in emerging channels and overseas markets [4]